Patient clinical and demographic characteristics total number
| Median age (range) | 60 (46-90) |
| Male, n (%) | 28 (78) |
| ECOG, n (%) | |
| 0/1 | 34 (94) |
| 2 | 2 (6) |
| Stage at initial diagnosis, n (%) | |
| I/II | 5 (14) |
| III/IV | 28 (78) |
| Unknown | 3 (8) |
| MIPI | |
| Low | 18 (50) |
| Intermediate | 7 (19) |
| High | 11 (31) |
| Extranodal disease at initial diagnosis, n (%) | 9 (25) |
| Induction therapy, n (%) | |
| BR | 17 (47) |
| R-HyperCVAD | 9 (25) |
| Nordic Regimen (maxi-RCHOP/HiDAC) | 7 (19) |
| R-CHOP/DHAP | 2 (6) |
| R-CHOP | 1 (3) |
| auto-SCT consolidation before enrollment, n (%) | 18 (50) |
| Best response to induction therapy before enrollment, n (%) | |
| CR | 34 (94) |
| PR | 2 (6) |
| MRD status after induction therapy (n = 22) | |
| MRD (−)∗ | 17 (77) |
| MRD indeterminate (defined as <1 × 106 cells assayed) | 4 (18) |
| MRD (+)† | 1 (5) |
| Median age (range) | 60 (46-90) |
| Male, n (%) | 28 (78) |
| ECOG, n (%) | |
| 0/1 | 34 (94) |
| 2 | 2 (6) |
| Stage at initial diagnosis, n (%) | |
| I/II | 5 (14) |
| III/IV | 28 (78) |
| Unknown | 3 (8) |
| MIPI | |
| Low | 18 (50) |
| Intermediate | 7 (19) |
| High | 11 (31) |
| Extranodal disease at initial diagnosis, n (%) | 9 (25) |
| Induction therapy, n (%) | |
| BR | 17 (47) |
| R-HyperCVAD | 9 (25) |
| Nordic Regimen (maxi-RCHOP/HiDAC) | 7 (19) |
| R-CHOP/DHAP | 2 (6) |
| R-CHOP | 1 (3) |
| auto-SCT consolidation before enrollment, n (%) | 18 (50) |
| Best response to induction therapy before enrollment, n (%) | |
| CR | 34 (94) |
| PR | 2 (6) |
| MRD status after induction therapy (n = 22) | |
| MRD (−)∗ | 17 (77) |
| MRD indeterminate (defined as <1 × 106 cells assayed) | 4 (18) |
| MRD (+)† | 1 (5) |